SCHEDULE: Woodline Partners Discloses 5.6% Stake in Tango Therapeutics
Beneficial Ownership Disclosure
Woodline Partners LP has disclosed a 5.6% passive ownership stake in Tango Therapeutics, Inc., holding over 6 million shares of common stock.
Summary
- Woodline Partners LP, a Delaware limited partnership and investment adviser, reported beneficial ownership of 6,029,906 shares of Tango Therapeutics, Inc. common stock.
- This stake represents 5.6% of Tango Therapeutics' total outstanding common stock.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
- The percentage of ownership is calculated based on 108,394,190 shares of common stock outstanding as of May 5, 2025, as reported in Tango Therapeutics' Quarterly Report on Form 10-Q filed on May 12, 2025.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a passive ownership stake, which is neutral in itself. However, the disclosure of a significant stake by an institutional investor like Woodline Partners can be perceived as a mild positive signal of confidence in the company's value.
Positives
- A notable investment firm, Woodline Partners LP, has taken a significant 5.6% stake in Tango Therapeutics, indicating potential institutional confidence in the company's long-term prospects.
Negatives
- No specific negative aspects related to Tango Therapeutics' operations or financial health were disclosed in this ownership filing.
Risks
- The filing explicitly states that the reporting person's beneficial ownership should not be construed as an admission of beneficial ownership for the purposes of Section 13 of the Securities Exchange Act of 1934.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment adviser, common in the biotechnology and pharmaceutical sectors where institutional investors frequently take positions in emerging or specialized companies.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: Provides increased transparency regarding significant institutional ownership in the company.
- Investment Community: Offers insight into the positions taken by large institutional investors, which may influence broader market sentiment towards Tango Therapeutics.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 05/05/2025 | Date as of which 108,394,190 shares of Common Stock were outstanding, as reported in the Company's Quarterly Report on Form 10-Q. |
| 05/12/2025 | Date Tango Therapeutics filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025. |
| 06/30/2025 | Date of event which required the filing of this statement (trigger date for the 5% ownership threshold). |
| 08/14/2025 | Date the Schedule 13G was signed and filed by Woodline Partners LP. |
Keywords
Tango Therapeutics, Woodline Partners, SEC filing, Schedule 13G, beneficial ownership, common stock, investment adviser, biotechnology, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.